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Abstract 
Kaposi sarcoma-associated herpesvirus (KSHV) ORF57, also known as Mta (mRNA transcript 
accumulation), enhances viral intron-less transcript accumulation and promotes splicing of 
intron-containing  viral  RNA  transcripts.  In  this  study,  we  identified  KSHV  PAN,  a  long 
non-coding polyadenylated nuclear RNA as a main target of ORF57 by a genome-wide CLIP 
(cross-linking and immunoprecipitation) approach. KSHV genome lacking ORF57 expresses 
only a minimal amount of PAN. In cotransfection experiments, ORF57 alone increased PAN 
expression by 20-30-fold when compared to vector control. This accumulation function of 
ORF57 was dependent on a structured RNA element in the 5' PAN, named MRE (Mta re-
sponsive element), but not much so on an ENE (expression and nuclear retention element) in 
the 3' PAN previously reported by other studies. We showed that the major function of the 
5' PAN MRE is increasing the RNA half-life of PAN in the presence of ORF57. Further mu-
tational analyses revealed a core motif consisting of 9 nucleotides in the MRE-II , which is 
responsible for ORF57 interaction and function. The 9-nt core in the MRE-II also binds cellular 
PABPC1, but not the E1B-AP5 which binds another region of the MRE-II. In addition, we found 
that PAN RNA is partially exportable in the presence of ORF57. Together, our data provide 
compelling evidence as to how ORF57 functions to accumulate a non-coding viral RNA in the 
course of virus lytic infection. 
Key  words:  KSHV,  long  non-coding  RNA,  ORF57,  PAN,  RNA  stability,  RNA  accumulation, 
PABPC1, E1B-AP5 
Introduction 
Kaposi's  sarcoma-associated  herpesvirus 
(KSHV), also known as human herpesvirus 8 (HHV8), 
belongs to the gamma herpesvirus family and is the 
causative agent for Kaposi's sarcoma, the most com-
mon AIDS-associated cancer [1-3]. KSHV is also asso-
ciated with other lymphotropic malignancies, such as 
primary  effusion  lymphoma  (PEL)  and  multicentric 
Castleman's disease [4,5]. Similar to  other  herpesvi-
ruses, KSHV undergoes two distinguishable viral life 
cycles: latency and a lytic replication. However, and 
unlike other viruses, the KSHV latent program does 
not  efficiently  immortalize  virus  infected  cells  [6,7]. 
Experimental evidence also indicates that viral factors 
encoded during the lytic cycle, such as paracrine sig-
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nals [8], or viral proteins, like the G protein-coupled 
receptor (vGPCR) [9,10], might supply the inflamma-
tory  and  angiogenic  components  required  for  cell 
transformation [7].  
 Given the importance of the KSHV lytic cycle, 
we are interested in the mechanisms underlying the 
regulation of viral lytic gene expression. During the 
lytic  cycle,  KSHV  expresses  two  main  regulatory 
proteins:  ORF50  (Rta,  replication  and  transcription 
activator)  which  initiates  transcription  of  viral  lytic 
genes [11,12] and ORF57 (Mta, mRNA transcript ac-
cumulation), a multifunctional protein that promotes 
the  accumulation  of  viral  intron-less  transcripts 
[13-17]  and  stimulates  intron  removal  of  viral  in-
tron-containing  RNAs  [18,19].  The  intron  removal 
function of ORF57 is especially important for the vi-
rus, as pre-mRNA lacking appropriate posttranscrip-
tional processing is less stable than its properly pro-
cessed functional counterpart [20]. Lytic KSHV repli-
cation  also  promotes  widespread  shutoff  of  cellular 
gene  expression  by  hyperadenylation  and  nuclear 
retention of host mRNA which leads to enhancement 
of cellular mRNA turnover [21-23]. Thus, it is no sur-
prise that KSHV has evolved mechanisms for regu-
lating the ORF57-mediated post-transcriptional viral 
RNA  processing  and  accumulation.  To  understand 
how ORF57 functions in host cells is a key step to de-
termine how KSHV ensures the expression of its own 
genes,  while  also  shutting-off  host  gene  expression 
during virus lytic infection. Previously, we have de-
scribed a mechanism as to how ORF57 stimulates the 
expression of intron-containing viral RNA transcripts 
in [18]. However, it remains unclear how ORF57 ac-
cumulates  intron-less  viral  RNAs,  and  whether  the 
accumulation is mediated by interfering with nuclear 
export [13,16,24-26].  
 Recently,  we  conducted  a  genome-wide  CLIP 
(UV-crosslinking  and  immunoprecipitation)  assay 
from B cells with KSHV lytic infection and identified 
11  viral  transcripts  as  putative  ORF57  targets  [27]. 
One of those targets was vIL-6, which stimulates cell 
proliferation  during  KSHV  infection  [8].  We  found 
that  vIL-6  RNA  contains  an  ORF57  responsive  ele-
ment. ORF57 binding to this element in vIL-6 RNA 
stabilizes vIL-6 RNA and promotes vIL-6 translation 
by interfering with miR-1293-mediated vIL-6 mRNA 
repression [27]. 
 Subsequently,  we  identified  PAN  RNA  (poly-
adenylated nuclear RNA) as a major target of ORF57 
and, therefore, became interested in whether ORF57 is 
also involved in modulating PAN RNA metabolism. 
PAN is the most abundant viral transcript, constitut-
ing ~80% of all polyadenylated transcripts  in a cell 
with  lytic  KSHV  infection  [28,29].  PAN  is  a  long 
non-coding, polyadenylated nuclear RNA transcribed 
by RNA polymerase II [28-30] which differs from EBV 
non-coding, small nuclear RNAs, EBER-1 and EBER-2 
transcribed  by  RNA  polymerase  III  [31].  In  the  nu-
cleus,  PAN  forms  a  speckled  pattern  typical  of  U 
snRNAs and colocalizes with Sm protein [28,32]. We, 
along  with  other  groups,  have  shown  that  ORF57 
promotes PAN RNA accumulation [14,33]. Previous 
studies  showed  that  PAN  RNA  stability  in  the  ab-
sence of ORF57 seems to be dependent on the activity 
of a cis-acting 79-nucleotide (nt) RNA element located 
in  the  3'  PAN,  called  ENE  (expression  and  nuclear 
retention element)[34-37]. In the absence of the ENE, 
PAN’s stability appears to rely on ORF57 binding to a 
5' motif [38]. In this report, we identified a 9-nt core 
motif  in  the  5'  PAN  region  that  is  responsible  for 
ORF57-mediated  PAN  accumulation.  The  element 
containing the core motif is designated as MRE (Mta 
responsive  element)  and  its  major  function  is  in-
creasing the half-life of PAN RNA in the presence of 
ORF57. In contrast, the ENE plays only a small role in 
ORF57-mediated  accumulation  of  PAN.  We  found 
that the PAN MRE interacts with ORF57 and cellular 
proteins PABPC1 and E1B-AP5.  
Materials and methods 
Cells 
 Human HEK293 and HeLa cells were cultivated 
in  Dulbecco's  modified  Eagle  medium  (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine 
serum  (FBS,  HyClone,  Logan,  UT),  2  mM 
L-glutamine,  100  U/ml  penicillin,  and  100  μg/ml 
streptomycin  (Invitrogen).  HEK293  cell  lines  stably 
harboring  a  KSHV  wt  genome  (Bac36-wt)  or  an 
ORF57-null KSHV genome (Bac36-Δ57) [33] were in-
duced with 1 mM valproate (VA) for lytic infection. 
JSC-1 cells (KSHV+/EBV+) and BCBL1 cells (KSHV+) 
were grown in RPMI 1640 containing 10% FBS and 
were  induced,  respectively,  with  sodium  butyrate 
(Bu, 3 mM) and VA (1 mM) for lytic infection. TREx 
BCBL1-vector  and  TREx  BCBL1-Rta  cells  [39]  were 
cultivated in RPMI 1640 supplemented with 10% FBS 
and hygromycin B (50 μg/ml). To induce the expres-
sion of KSHV lytic genes, TREx BCBL1-Rta or TREx 
BCBL1-vector  (a  negative  control)  cells  at  5  x  105 
cells/ml were seeded and cultivated for 24 h in the 
presence of 1μg/ml of doxycycline (Dox). 
Mammalian expression vectors 
 Mammalian  expression  vectors  pVM7  (for 
FLAG-tagged ORF57), pVM8 (for GFP-tagged ORF57) 
and  pVM36  (for  GFP-tagged  inactive  ORF57  with 
point  mutations  in  NLS2+3  or  ORF57  mtNLS2+3) Int. J. Biol. Sci. 2011, 7 
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were  described  in  our  previous  report  [13].  KSHV 
ORF50 (Rta) expression vector has been used in our 
laboratory for various studies [33,40]. Other plasmids 
used in this study and the oligos and strategy used for 
their construction are listed in Supplementary Mate-
rial: Table S1. See oligo sequences in Supplementary 
Material: Table S2. Overlapped PCR for mutant con-
structions was performed as described [41].  
Transient transfection assay 
 Cotransfection  of  expression  vectors  PAN  (wt 
and  mutants),  vGPCR,  or  K5  was  performed  in 
HEK293 or HeLa cells (5 x105 cells/well) in a six-well 
plate, with 1 μg of individual vector together with 0.2 
μg (5:1 ratio) of pVM7 (ORF57-FLAG fusion) [13] or 
an  empty  pFLAG-CMV-5.1  vector  using  Lipofec-
tamine 2000 (Invitrogen).  
Western blot 
 Protein samples for Western blotting were pre-
pared by direct lysis of the cells in 0.5 ml of 2X SDS 
sample buffer (Quality Biological, Inc., Gathersburg, 
MD)  plus  10%  2-mercaptoethanol.  Samples  were 
boiled and resolved in a 4%-12% SDS-polyacrylamide 
gel by electrophoresis. The following antibodies were 
used  in  Western  blot  analyses:  a  rabbit  polyclonal 
anti-ORF57  antibody  [33](1:3,000  dilution),  mouse 
monoclonal anti-ORF57 antibody (unpublished data, 
used  at  a  dilution  of  1:1,000),  rabbit  polyclonal  an-
ti-PABPC1 (1:700, Abcam ab21060), and rabbit poly-
clonal  anti-E1B-AP5  (1:1,000,  ProteinTech  Group 
0578-1-AP, Chicago, IL), together with corresponding 
peroxidase-conjugated  secondary  antibodies 
(1:10,000, Sigma). The signal on the western blot was 
detected with West Pico chemiluminiscence substrate 
(Pierce, Rockford, IL).  
RNA preparation and Northern blot 
 Total cell RNA samples were prepared 24 or 48 h 
after transfection (HEK293, HeLa) or after induction 
(B cells) by the addition of 1 ml of TRIzol reagent ac-
cording  to  the  TRIzol  protocol  (Invitrogen).  Cyto-
plasmic and nuclear total RNAs were fractionated as 
described [13]. RNA (~5 μg) was separated in a 1% 
agarose gel and analyzed by Northern blotting [13]. 
PAN, K5 and vGPCR RNAs expressed from individ-
ual  plasmids  were  detected  with  2  ×  106  cpm  of  a 
γ-32P-labeled T7 probe oZMZ243 (see Supplementary 
Material: Table S2 for sequence details). PAN was also 
detected  with  a  PAN-specific  probe  oJM7  (Supple-
mentary Material: Table S2). ORF57 was detected with 
an oligo probe oVM11 (Supplementary Material: Ta-
ble S2). The hybridization signal was captured using a 
Molecular Dynamics PhosphorImager Storm 860 and 
analyzed with ImageQuant software. 
CLIP and RT-PCR 
 CLIP assays were conducted as described [27]. 
RT-PCR  was  performed  by  using  a  PAN-specific 
primer pair oVM52 and oJM7 on DNase-treated total 
RNA  extracted  from  the  CLIP  complexes  obtained 
with an anti-ORF57 antibody or rabbit IgG (a negative 
control). 
Luciferase Assays 
 To evaluate luciferase activity in HEK293 cells, 
2.5 x105 cells were grown in 24-well plates and trans-
fected  with  50  ng  of  each  firefly  luciferase  reporter 
plasmid  (pMIR-REPORT-Luciferase  reporter  or  its 
derived pJM19, pJM43 and pJM44, see Supplementary 
Material: Table S1 for details) together with 10 ng of 
Renilla  luciferase  reporter  (pRL-TS)  [42]  using 
Lipofectamine 2000. Cells were harvested in dual lu-
ciferase assay 1x lysis buffer (Promega, Madison, WI). 
To  evaluate  activity  in  TREx  BCBL1  cells,  2.5  x105 
TREx BCBL1-Rta cells were grown in 24-well plates 
for  24  h  and  the  reactivated  by  addition  of  Dox  (1 
μg/ml). One hour after Dox addition, the cells were 
transfected with 100 ng of each firefly and Renilla lu-
ciferase reporter plasmid (psiCHECK2 or its derived 
pJM47,  pJM48,  pJM49,  pJM50  and  pJM51,  see  Sup-
plementary  Material:  Table  S1  for  details)  using 
FugeneHD  transfection  agent  (Roche  Diagnostics, 
Indianapolis,  IN).  24  h  after  transfection,  the  cells 
were harvested in dual luciferase assay 1x lysis buffer. 
The  volume  of  the  buffer  added  was  adjusted  ac-
cording  to  cell  number  of  each  testing  condition  in 
order to obtain an equal amount of protein levels of 
induced vs un-induced conditions. Luciferase activity 
measured from cell lysate supernatant using a Glo-
Max®-Multi  Microplate  Multimode  Reader 
(Promega) was expressed in ratios of firefly to Renilla 
(F/R for HEK293 cells) or Renilla to firefly (R/F for 
TREx BCBL1-Rta cells). 
 We performed a mixed model ANOVA on lu-
ciferase activities (Fig. 5D). An eight level treatment 
group  (4  plasmids  x  2  treatments)  was  used  as  the 
fixed  effect.  Two-tailed  p-values  were  determined 
after  adjusting  for  the  number  of  comparisons  per-
formed, using a standard method (due to Holm). Re-
siduals were examined for normality and homogene-
ity and were partitioned if found to be heterogeneous.  
RNA-protein pulldown assay 
 Total cell extracts used in RNA pulldown assays 
were prepared from ~5 x 106 of TREx BCBL1-Rta or 
-vector cells which were reactivated by Dox (1 μg/ml) Int. J. Biol. Sci. 2011, 7 
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for 24 h. The cells were harvested by centrifugation at 
800 x g at 4oC for 5 min, washed twice with 1 x PBS 
and resuspended in 500 μl (Rta cells) or 1000 μl (vector 
cells) of 1x RIPA buffer containing protease inhibitor 
(Complete Mini EDTA-free Protease Inhibitor Cock-
tail, 1x, Roche). The samples were incubated for 10 
min on ice, briefly sonicated (10 times at level 4), and 
centrifuged for 25 min at 10,000 x g at 4oC. The extract 
supernatant ready for RNA pulldown was aliquoted 
and stored at -20oC. 
 RNA  pulldown  assay  using  biotinylated  RNA 
oligomers  was  performed  as  described  [27,43].  The 
following  RNA  oligos  used  in  the  pulldowns  and 
schematized  in  Fig.  6A  were  oJM32,  oJM33,  oJM34, 
oJM35  and  oJM68  (see  sequence  details  in  Supple-
mentary Material: Table S2). RNA oligos oNP41 and 
oNP42 derived from vIL-6 RNA served, respectively, 
as a negative and positive control for ORF57 binding 
[27]. The proteins in the pulldowns were analyzed by 
Western blot. Alternatively, the proteins resolved in a 
4%-12% SDS-PAGE gel were silver-stained using Sil-
verQuest™  Silver  Staining  Kit  (Invitrogen)  and  the 
corresponding proteins in a separate gel without sil-
ver  staining  were  gel-purified  and  identified  using 
Nano  LC-MS/MS  peptide  sequencing  technology 
(ProtTech, Inc., Norristown, PA). 
RNA stability assay 
 PAN decay was analyzed in HEK293 cells tran-
siently  transfected  with  individual  PAN  expression 
plasmids in the presence or absence of ORF57. Since 
PAN is expressed at a very low level in the absence of 
ORF57, HEK293 cells (1x 106) in 60-mm dishes were 
cotransfected using FuGene HD (Roche) with 4 μg of a 
wt PAN expression plasmid plus 800 ng of an empty 
pFLAG-CMV-5.1 vector, 20-times more PAN expres-
sion vector in the absence of ORF57 than its transfec-
tion in a 24-well plate in the presence of ORF57. Re-
al-time PCR for PAN and GAPDH RNA was carried 
out  on  the  cDNA  in  duplicates  as  described  previ-
ously [26]. GAPDH RNA levels remained constant in 
the course of the experiments by normalization with 
β-actin  RNA.  The  following  PAN  TaqMan  primers 
from IDT (Coralville, IA) were used: PAN Probe; PAN 
primer  1;  PAN  primer  2  (Supplementary  Material: 
Table S2). The relative expression of PAN was deter-
mined using 2-ΔΔCT method [27,44,45] and converted 
to percentage, with the amount at time zero of acti-
nommycin  D  (act.  D)  addition  as  100  %.  The  RNA 
decay represents remaining RNA (%) over the time 
zero  in  the  presence  or  absence  of  ORF57.  A 
non-linear  regression  analysis  on  the  raw  data  was 
performed and applied to an exponential decay mod-
el [Fold Percent = α*exp(β*time)], where α (alpha) is 
the intercept when time = 0, and β (beta) is the decay 
rate.  Alpha  was  constrained  to  be  equal  to  100% 
(α=100%), and beta to be less than or equal to zero 
(β<=0). Comparison of beta parameter estimates be-
tween  the  treatments  was  performed  by  using  a 
model  with  a  dummy  variable  (model  based 
two-tailed  p-value  via  t-test).  The  half-life  for  each 
treatment was estimated by letting the fold percent 
equal 50% and solving for time.  
Results 
PAN is associated with ORF57 in B cells with 
KSHV lytic infection and responds to ORF57 
function 
 Among  11  potential  RNA  targets  of  ORF57 
identified in B cells with KSHV lytic infection by an 
anti-ORF57  CLIP  assay  [27],  PAN  RNA  sequences 
were  pulled  down  more  than  90  times,  listing  the 
PAN  as  one  of  the  most  prominent  targets  in  the 
ORF57  CLIP  assays.  Considering  PAN  is  the  most 
abundant KSHV RNA constituting ~80% of all poly-
adenylated transcripts in a cell with lytic KSHV infec-
tion  [28,29],  the  high  frequency  of  PAN  sequences 
identified  in  the  ORF57  CLIP  assays  might  simply 
reflect the abundance of PAN in an RNA pool of the 
KSHV-infected  B  cells.  However,  when  aligned 
against  the  KSHV  genome,  the  isolated  PAN  se-
quences  were  clustered  mainly  at  the  5'-half  (nt 
28667-28750  with  16  sequence  tags)  and  3'-half  (nt 
29544-29658  with  43  sequence  tags)  of  PAN  (NCBI 
accession  no.:  U75698)  [46],  along  with  a  fewer  se-
quence tags clustering in the middle regions of PAN 
[Supplementary  Material:  Fig.  S1,  also  see  Supple-
mentary Material: Table S1 in the reference [27]], in-
dicating  a  sequence-specific  PAN  association  of 
ORF57 in B cells with KSHV lytic infection. Interest-
ingly, the PAN 3' region interacting with ORF57 en-
compasses a structured ENE (expression and nuclear 
retention  element)  previously  identified  for  the  nu-
clear abundance of PAN [34] through its U-rich in-
ternal loop interacting with the PAN poly (A) tail [36]. 
 The interaction between PAN RNA and ORF57 
in B cells with KSHV lytic infection was then verified 
using CLIP/RT-PCR, by which PAN RNA was spe-
cifically pulled down with an anti-ORF57 antibody, 
but not an IgG control (Fig. 1A). Previous studies have 
demonstrated  a  role  of  ORF57  in  PAN  expression 
[14,33]. Consistent with these findings, we observed 
that  PAN  expression  was  increased  during  lytic 
KSHV induction in two B cell lines BCBL-1 (Fig. 1B, 
compare lane 1 to lane 2) and JSC-1 (Fig 1B, compare 
lane 5 to lane 6).  Int. J. Biol. Sci. 2011, 7 
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Fig.  1.  PAN  expression  depends  on  viral  ORF57.  (A) 
ORF57  binds  PAN  RNA  during  lytic  KSHV  infection. 
RT-PCR was performed by using a PAN-specific primer pair 
on total RNA isolated from the CLIP complexes obtained 
with an anti-ORF57 antibody from butyrate-treated JSC-1 
cells. (B) PAN expression depends on ORF57 during lytic 
KSHV  infection.  Total  RNA  obtained  from  BCBL-1  and 
JSC-1 cells induced with butyrate (Bu, 3 mM) or from Bac36 
cells  with  a  wild-type  KSHV  genome  (Bac36  wt)  and 
Bac36-Δ57 cells with an ORF57-null KSHV genome [33] 
induced with VA (1 mM) was examined by Northern blot 
for PAN RNA with a PAN-specific probe oJM7. GAPDH 
RNA served as a loading control. (C) ORF57 enhances PAN 
accumulation at the posttranscriptional level. Total RNA 
from HEK293 cells transfected with an expression vector of 
PAN, K5 or vGPCR (see diagrams) or an empty pcDNA3 
vector,  together  with  a  FLAG-tagged  ORF57  (+)  or  an 
empty FLAG vector (-) was examined by Northern blot 
with a T7 probe for expression of PAN, K5 or vGPCR. (D) 
ORF57 inactive mutant (mtNLS2+3) is unable to enhance 
PAN expression. Total RNA from HEK293 cells transfected 
with a PAN expression vector together with a GFP-tagged 
ORF57 wt (ORF57 wild type), GFP-tagged ORF57 inactive 
mutant (mtNLS2+3) [13] or GFP empty vector pEGFP-N1 
was examined by Northern blot for PAN RNA. 
 
 
This  increase  of  PAN  expression  during  lytic 
KSHV infection, in the context of KSHV genome, is 
dependent on ORF57 expression. As shown in Fig. 1B, 
Bac36-wt cells with stable transfection of a wt KSHV 
genome responded to viral lytic induction by VA for 
PAN  expression,  but  Bac36-Δ57  cells  with  stable 
transfection of an ORF57-null KSHV genome did not 
(compare lane 3 to lane 4). By cotransfection analyses 
of HEK293 cells, we further demonstrated that PAN 
was the most prominent responder (~35-fold increase) 
to ORF57 in the absence of other viral proteins when 
comparing with KSHV K5 and vGPCR (Fig. 1C), alt-
hough expression of all three tested genes in the vec-
tor were driven by the same cytomegalovirus (CMV) 
immediate-early  promoter.  Both  KSHV  K5  and 
vGPCR did not interact with ORF57 in our CLIP as-
says and were previously shown as a non-responder 
to ORF57 [14]. Consistently, we found only a slight 
increase of K5 (~5 fold) and vGPCR (~3 fold) in the 
presence of ORF57 in our cotransfection assays (Fig. 
1C).  Together,  these  data suggest  that  ORF57  regu-
lates PAN expression at the posttranscriptional level. 
When an ORF57 inactive mutant (a NLS2+3 mutant) 
[13]  was  included  for  comparison,  increased  PAN 
expression was found in the cotransfection with wt 
ORF57, but not with the mt ORF57 (Fig. 1D). Our data 
further indicate the specificity of ORF57 in posttran-
scriptional regulation of PAN expression. Int. J. Biol. Sci. 2011, 7 
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An MRE at the 5' end of PAN is required for 
ORF57 to accumulate PAN 
 Given  ORF57-specific  association  with  PAN 
sequences that could be clustered at three major re-
gions,  a  5'-end  region  (nt  28667-28750),  an  internal 
region  (nt  28971-29114),  and  a  3'-half  region  (nt 
29544-29658)  (Supplementary  Material:  Fig.  S1),  we 
constructed  a  series  of  PAN  deletion  mutants  (Fig. 
2A)  and  evaluated  the  relevance  of  these 
ORF57-binding  sequences  on  PAN  accumulation  in 
the presence or absence of ORF57 by cotransfection of 
HEK293 cells. As shown in Fig. 2B, we demonstrated 
that wt PAN, Δ2 mt with deletion of the internal re-
gion, and Δ3b mt with partial deletion of the 3'-half 
region were all higher responders to ORF57, despite a 
minor reduction of PAN expression observed in two 
mutants  in  the  presence  of  ORF57.  Deletion  of  the 
5'-end region was detrimental and greatly reduced the 
response  of  PAN  to  ORF57  function.  Interestingly, 
deletion of the entire 3'-half region (Δ3 mt) including 
the ENE only had a small (~ 2 fold) effect on PAN to 
ORF57.  From  this  analysis,  we  concluded  that  the 
5'-end region is essential for PAN RNA accumulation 
and  it  contributed  at  least  25-fold  enhancement  of 
PAN expression in the presence of ORF57 (Figure 2B). 
The ENE is a much  weaker element in response  to 
ORF57 and the internal region examined in the pres-
ence of ORF57 did not play a significant role in PAN 
expression. As a result, we designated the 5'-end re-
gion of PAN as a functional MRE.  
 
Fig. 2. ORF57-mediated enhancement of PAN expression depends on a 5' PAN element. Shown in (A) are schematic 
diagrams of wt PAN and its deletion mutants. Shaded and numbered boxes represent the positions of ORF57 interacting 
regions identified by CLIP in PAN: box 1 (black), a PAN 5' region from nt 28667-28750; box 2 (dark grey), a PAN internal 
region from nt 28971-29114; box 3 (hatched and solid grey), a PAN 3' region from nt 29544-29658 including the entire ENE 
(hatched grey, nt 29554-29632). Total RNA from HEK293 cells transfected with each of the PAN constructs in the presence 
(+) or absence (-) of ORF57 was examined by Northern blot with a T7 probe for PAN expression (B). The same membrane 
in each panel was stripped and reprobed separately with a 
32P-labeled ORF57 or GAPDH probe for ORF57 expression and 
sample loading. Relative levels of PAN RNA in each sample were shown at the bottom of each Northern blot panel after 
normalization to the level of the corresponding GAPDH for sample loading. Int. J. Biol. Sci. 2011, 7 
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PAN stability depends on both ORF57 and 
MRE 
 To further analyze the function of the MRE, we 
first evaluated the stability of PAN with or without 
the  identified  MRE  in  the  presence  or  absence  of 
ORF57. After inhibiting Pol II transcription in HEK293 
cells by treating with actinomycin D, we measured the 
remaining PAN RNA level over the time by RT-qPCR 
and the PAN RNA level was normalized to the cor-
responding GAPDH RNA level for sample loading. 
As  shown  in  Fig.  3,  PAN,  under  our  experimental 
conditions, was relatively unstable, with a half-life of 
3.87  h  in  the  absence  of  ORF57.  However,  in  the 
presence of ORF57, PAN became a significantly more 
stable transcript, with a half-life of 12.2 h, equating to 
a ~3-times longer half-life compared to its absence of 
ORF57.  Interestingly,  this  significant  (P=0.005)  in-
crease in decay rate of PAN by ORF57 was greatly 
decreased when the MRE was deleted from PAN. In 
the presence of ORF57, PANΔ1 with deletion of the 
MRE (Fig. 3) had a half-life of only 4.78 h, with the 
decay rates being significantly different than wt PAN 
under the same condition (P=0.042). The determined 
half-life (½ = 4.78 h) of the mt PAN in the presence of 
ORF57 was comparable with the half life (½ = 3.87 h) 
of wt PAN in the absence of ORF57, indicating that 
ORF57 enhances PAN expression by stabilizing PAN 
RNA through interaction with the MRE in the 5' re-
gion of PAN. 
 
Fig. 3. Stability of PAN depends on MRE and ORF57. (A) Calculation of half life of wt PAN and mt PANΔ1 lacking the 5' MRE 
in the presence or absence of ORF57. HEK293 cells were transfected with a vector expressing wt or mt PAN together with 
ORF57 or a vector control. 24 h after transfection, transcription was stopped by addition of 10 μg/ml of actinomycin D and 
total RNA was extracted from each sample collected over the time as indicated. PAN and GAPDH (for normalization) were 
quantified by qRT-PCR. The remaining level of PAN RNA in each time point relative to time zero was determined as de-
scribed in Methods, after normalization to GAPDH RNA for sample loading. Results are presented as mean, minimum and 
maximum. A non-linear regression analysis on the raw data was performed, choosing an exponential decay model [Fold 
Percent = α*exp(β*time) ] where α (alpha) is the intercept when time = 0, and β (beta) is the decay rate. (B) Summary of the 
estimated betas (Est. β) and its standard errors (SE) for each study group. Also included are the adjusted R-squares and 
calculated half-life for each study group as well as two-tailed p-values for the indicated pair-wise comparisons between the 
estimated parameters. The p-values for the estimated betas were adjusted using a step-down Bonferroni method. Int. J. Biol. Sci. 2011, 7 
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A 9-nt core in the MRE motif II (MRE-II) is 
necessary for ORF57-mediated PAN accumu-
lation 
 By alignment of all MRE sequence tags identi-
fied by ORF57 CLIP assays (Supplementary Material: 
Fig. S1A) in combination with RNA folding analysis, 
we found that the 84-nt MRE is composed of three 
stem-loop  structures  which  were  designated  as 
MRE-I, -II and III in the 5' to 3' order (See Fig. 4A for 
underlines and 4B for labels). Subsequently, we con-
structed a series of successive 5' to 3' deletions of the 
MRE into the MRE-I (ΔMRE-a), the MRE-I plus the 
MRE-II (ΔMRE-c) and an internal deletion of the en-
tire MRE-II (ΔMRE–d) in the context of PAN (Fig. 4A). 
By cotransfection of HEK293 cells in the presence or 
absence of ORF57, as shown in Fig. 4C and 4D, wt 
PAN expression increased almost 30-fold by ORF57 
when compared to its absence of ORF57, as expected. 
The expression of ΔMRE-a, with complete deletion of 
the MRE-I, also exhibited 34-fold increased PAN ex-
pression in the presence of ORF57 (Fig. 4C), whereas 
the  expression  of  ΔMRE-c,  with  deletion  of  both 
MRE-I  and  entire  MRE-II,  showed  a  significant  re-
duction in PAN expression when ORF57 was present 
(Fig.  4D).  The  expression  level  of  PAN  from  the 
ΔMRE-c (Fig. 4D) was similar to that observed in the 
MREΔ1  mutant  in  the  presence  of  ORF57  (Fig.  2). 
Collectively, these data indicate that the PAN MRE-II 
is  the  element  through  which  ORF57  functionally 
modulates  PAN  expression.  The  importance  of  the 
MRE-II  in  ORF57-mediated  PAN  expression  was 
further  verified  using  an  additional  construct 
ΔMRE-d, containing an internal deletion of the entire 
MRE-II (Fig. 4A and 4D). The level of PAN ΔMRE-d 
expression observed was comparable to that found for 
ΔMRE-c. 
 As ORF57 appears to preferentially interact with 
a single-stranded loop structure in the vIL-6 MRE [27] 
and other targeted RNAs (our unpublished data), and 
the PAN MRE-II contains an 11-nt loop, we next in-
troduced  random  point  mutations  into  the  MRE-II 
loop. The result was the creation of an MRE-PM (Fig. 
4A and 4B), and we tested its expression in HEK293 
cells along with wt PAN, ΔMRE-c and ΔMRE-d.The 
MRE-PM, with substitution of the 9 nts in the MRE-II 
loop, was impotent to respond to ORF57, when com-
pared with wt PAN and had a similar expression level 
observed  for  both  the  ΔMRE-c  and  ΔMRE-d  con-
structs (Fig. 4D). Our results indicate that the 9 nts 
(UAUGGAUUU) in the MRE-II loop function as an 
MRE core for ORF57 interaction in enhancing PAN 
expression. 
 To rule out any transcriptional effect caused by 
the CMV promoter in the tested PAN constructs, we 
replaced  the  CMV  promoter  from  the  CMV-PAN 
constructs with a native PAN promoter and evaluated 
ORF57 regulation of PAN expression from its native 
promoter in HEK293 cells (Fig. 4E, pJM53 for wt PAN 
and  pJM54  for  mt  PAN  [MRE-PM]).  KSHV  ORF50 
(Rta) was used to transactivate PAN expression from 
its native promoter [30,47] in the presence or absence 
of  ORF57.  In  the  absence  of  KSHV  Rta,  the  CMV 
promoter  maintained  the  ability  to  drive  PAN  ex-
pression, whereas the native promoter did not (Fig. 
4E, compare lane 3 to lane 1). Consistent with previ-
ous work [30,47], wt PAN, but not its mutant, could 
be transactivated in a dose-dependent manner from 
its native promoter by Rta in the absence of ORF57 
(Fig. 4E, compare lane 4 to lanes 6, 8, 10, 12, 14, and 
16). However, the expression of Rta-transactivated wt 
PAN, but not its mutant, from the native promoter 
could  be  remarkably  increased  in  the  presence  of 
ORF57 (Fig. 4E, compare lanes 5 to 7, lanes 9 to 11, and 
lanes 13 to 15). Our data indicate that the identified 
9-nt core in the MRE-II is indeed a functional core in 
the context of PAN and its native promoter. Moreo-
ver, Rta in a high dose (1000 ng) was found to trans-
activate  the  expression  of  wt  PAN,  but  not  the  mt 
PAN, to a prominent level (Fig. 4E, compare lane 14 to 
lane 16) in the absence of ORF57, suggesting instabil-
ity of the mt PAN lacking the 9-nt core in the MRE-II 
even  when  the  PAN  promoter  is  highly  active.  To-
gether, we conclude that, regardless of the promoter 
used  or  its  transcription  efficiency,  a  functional 
MRE-core in PAN RNA is essential for stabilization of 
PAN RNA and for interaction with ORF57. 
PAN MRE displays a limited function in the 
context of heterologous transcripts 
 To determine whether the PAN MRE can func-
tion  in  the  context  of  a  heterologous  transcript,  we 
examined  PAN  expression  using  the  vGPCR  con-
struct, an ORF57 insensitive responder (Fig. 1C). We 
first introduced either the entire MRE or the MRE-II 
upstream of the vGPCR sequence (Fig. 5A) to mimic 
its native position in PAN and found, in cotransfected 
HEK293 cells, that the vGPCR, regardless of whether 
accompanied with the insertion of the MRE-II (sense 
or antisense [as]) or the entire MRE, remained to be 
insensitive to ORF57(Fig. 5B). A minimal increase (~3 
fold) of vGPCR  RNA expression in  the presence of 
ORF57  was  found  in  all  vGPCR  expression  vectors 
with or without insertion of the MRE (compare pJM6 
to pJM18) and was independent of the MRE-II orien-
tation (compare pJM12 to pJM13).  
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Fig. 4. Motif II (MRE-II) of the PAN 5' MRE is necessary for ORF57 enhancement of PAN expression. (A) Schematic diagrams 
of the 5' MRE and its mutants. Shown on the top indicates an 84-bp MRE in the 5' PAN which contains three potential motifs 
(stem-loops) marked as I, II and III, with the sequences underlined. A series of successive 5' to 3' deletions in the 5' MRE, an 
internal deletion or point mutations in the MRE-II are shown as ΔMRE-a, -c, -d and MRE-PM. Nucleotide substitutions in the 
MRE-II sequence in an MRE-PM mutant are boxed. (B) Predicted secondary structures of the MRE. On the left is the 
secondary structure of wt MRE with a folding energy of -19.5 Kcal/mol, consisting of 3 stem-loops I, II, III as described in (A). 
On the right show the point mutations introduced into the MRE-II loop to create an MRE-PM construct. (C, D) Mapping of 
a 9-nt core in the MRE-II responsible for ORF57 enhancement of PAN expression. Total RNA of HEK293 cells transfected 
separately with an indicated PAN construct in (A), together with an ORF57 expression vector (+) or an empty vector (-) was 
examined for PAN expression by Northen blot with a 
32P-labeled T7 probe. (E) The MRE element in the presence of ORF57 
promotes PAN accumulation in the context of its native promoter. The upper panel show schematic diagrams of PAN Int. J. Biol. Sci. 2011, 7 
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expression driven by a CMV promoter (pJM1) or by a native PAN promoter (PANPr) (pJM53 for wt PAN and pJM54 for mt 
PAN [MRE-PM]). HEK293 cells transfected with each of these constructs in the presence (+) or absence (-) of ORF57 were 
analyzed for PAN expression by Northern blot with a 
32P-labeled PAN-specific probe oJM7 (Supplementary Material: Table 
S2). Relative PAN expression levels (fold) were quantified based on the density of each band after normalization to GAPDH 
for sample loading and were shown at the bottom of each blot, with the PAN level in the absence of ORF57 in (C, D) as 1 for 
each PAN construct and wt PAN level in the absence of both ORF57 and ORF50 in (E) as 1 for comparison. 
 
 
 
Fig. 5. The identified PAN MRE does not function efficiently in the expression of heterologous genes vGPCR and Luciferase. 
(A) Schematic diagrams of the vGPCR constructs. The MRE-II motif or the entire MRE was inserted upstream of vGPCR 
(pJM6, Fig. 1C) either in the sense or antisense (As) orientation as indicated by the arrow. (B) Effect of the MRE on vGPCR 
expression in the presence or absence of ORF57. Total RNA of HEK293 cells transfected with each of the constructs in (A), 
together with an ORF57 expressing vector (ORF57 +) or an empty vector (-), was examined for vGPCR expression by 
Northern blot with a 
32P-labeled T7 probe. Relative vGPCR expression level (fold) is shown at the bottom of Northern blots 
after normalization to GAPDH. (C) Schematic Diagrams of the firefly luciferase constructs. The entire MRE and/or ENE 
elements were inserted upstream (MRE) or downstream (ENE) of the firefly luciferase ORF, respectively, to mimic their 
native locations in PAN. (D) Effect of the MRE on luciferase expression in the presence or absence of ORF57. HEK293 cells 
were cotransfected with each firefly luciferase reporter construct, together with a Renilla luciferase pRL-TS construct [42] 
and a FLAG-tagged ORF57 expressing vector or an empty FLAG vector (FLAG). 24 h after transfection cells were lysated 
and luciferase activity was measured by a dual luciferase assay. Relative luciferase activity in each sample was calculated by 
dividing the light unit readings obtained from a tested firefly luciferase reporter construct by the light unit readings obtained 
from the Renilla luciferase reporter (F/R ratio). Luciferase activities (mean ± 95% confidence limits) from a mixed model 
analysis of variance are presented along with an adjusted two-tailed p-value. Int. J. Biol. Sci. 2011, 7 
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 Given that MRE functions in PAN containing an 
ENE on the 3' end, we then examined the MRE action 
in the context of the PAN ENE in different luciferase 
reporters as diagramed in Fig. 5C. The first set (Set 1) 
of  the  expression  vectors  were  derived  from  a 
pMIR-REPORT-Luciferase vector, with the MRE up-
stream and the ENE downstream of the firefly lucif-
erase ORF. A Renilla luciferase for dual luciferase as-
says was expressed from a separate reporter, pRL-TS 
[42]. The second set (Set 2) of expression vectors not 
diagramed in Fig. 5C was derived from a psiCHECK2 
vector  expressing  both  Renilla  luciferase  and  firefly 
luciferase from the same vector, with the MRE (sense 
for pJM47 or antisense for pJM48) upstream and/or 
the  ENE  (sense  for  pJM49  or  antisense  for  pJM50) 
downstream of the Renilla luciferase ORF. When each 
of  the  set  1  reporters  was  transfected  into  HEK293 
cells,  together  with  a  Renilla  luciferase  reporter 
pRL-TS and a FLAG-ORF57 or empty FLAG vector 
(Fig. 5D), the PAN-MRE upstream (pJM19), but not 
the PAN ENE downstream (pJM43), of the lucifease 
ORF was found to increase (P=0.011) luciferase activ-
ity only in the presence of ORF57. Under the same 
condition, no synergistic effect was seen for the MRE 
upstream and the ENE downstream of luciferase on 
the same vector (pJM44) (Fig. 5D). These data indicate 
that  the  PAN  MRE  could  function  weakly  in  a  se-
lected  heterologous  transcript  in  the  presence  of 
ORF57 and other sequence motif(s) in PAN other than 
the  ENE  are  needed  for  the  MRE  to  fully  function. 
This  interpretation  was  further  verified  in 
Dox-induced TREx BCBL1-Rta cells by transfection of 
the set 2 expression vectors (data not shown).  
A 9-nt core in the MRE-II loop interacts with 
ORF57, PABPC1 and E1B-AP5 
 As  shown  in  Fig.  4,  PAN  stability  requires  a 
functional MRE-II and ORF57. To provide direct bio-
chemical evidence of  the  9-nt core RNA interacting 
with  ORF57  protein,  we  performed  a  biotinylat-
ed-RNA pull-down assay [27,43] using a series of bio-
tinylated  RNA  oligomers  covering  the  entire  PAN 
MRE-II and MRE-III (oJM32, oJM33, oJM34, oJM35) 
(Fig. 6A). RNA oligomers from the MRE-I stem-loop 
were excluded since deletion of this stem-loop from 
PAN did not affect PAN accumulation in response to 
ORF57 (ΔMRE-a in Fig. 4A and 4C). When these RNA 
oligomers  were  compared  in  pulling  down  ORF57 
expressed from Dox-induced TREx BCBL1-Rta cells, 
the oJM35 oligomer which covers the entire 9-nt core 
of MRE-II loop was found to efficiently bind ORF57 in 
a level comparable to an vIL-6 RNA oligomer oNP42, 
a positive ORF57-binding oligomer [27], but all other 
oligomers showed less binding affinity to ORF57 (Fig. 
6A).  
 Subsequently,  oJM35  was  used  to  search  for 
ORF57  protein  partners  capable  of  binding  to  the 
MRE. Proteins pulled down with oJM35 from total cell 
extract  of  Dox-induced  TREx  BCBL1-Rta  cells  was 
identified  by  Nano  LC-MS/MS  peptide  sequencing 
technology.  We  found  oJM35  interacting  efficiently 
with  cellular  PABPC1  and  a  heterogeneous  nuclear 
ribonucleoprotein  E1B-AP5  (E1B 
55-kilodalton-associated protein or hnRNPUL1). This 
could  be  further  verified  by  RNA  pulldown  and 
Western  blot  analyses  (Fig.  6B),  showing  that  only 
oJM35  containing  an  intact  9-nt  core  in  the  MRE-II 
could  interact  efficiently  with  ORF57  and  PABPC1 
from TREx BCBL1-Rta cell extract (Fig. 6B, compare 
lane 4 to lane 5). Other RNA oligomers oJM32, oJM33 
and oJM34 do not have a 9-nt core and showed less 
affinity to these three proteins (Fig. 6B, compare lanes 
1-3 to lane 4). However, oJM35 appeared to interact 
with  E1B-AP5  independently  of  ORF57  because  it 
bound E1B-AP5 in TREx BCBL1-vector cells express-
ing no ORF57 (Fig. 6B, compare lane 4 to lane 5). A 
reduced level of E1B-AP5 interaction with oJM35 in 
the pulldowns with TREx BCBL1-Rta cell extract (R) 
than with TREx BCBL1-vector cell extract (V) (Fig. 6B, 
compare lanes 4 to 5 and lanes 9 to 10) suggests a re-
duced  expression  of  E1B-AP5  in  TREx  BCBL1-Rta 
cells (Fig. 6B, compare lane 17 to 18 for the input). 
More importantly, we found that PABPC1, similar to 
ORF57, bound wt MRE-core RNA (oJM35), but not its 
mutant form (oJM68) (Fig. 6B, compare lines 4-5 and 
9-10 to lanes 11-12), which is in contrast to E1B-AP5 
binding both wt and mt RNA oligomers. The oJM68 
has  the  same  sequence  as  oJM35,  but  its  9-nt  core 
UAUGGAUUU was changed to CUGCACGUC and 
this mutation in the context of PAN gene was suffi-
cient  to  inactivate  PAN  expression  in  response  to 
ORF57 (Fig. 4D and 4E). In addition, we found that 
PABPC1 binding to oJM35 took place more efficiently 
with the ORF57 expressing cell extract than with the 
ORF57 lacking one, but its binding to oNP42, a vIL-6 
MRE-derived RNA oligomer [27], could be found for 
both  cell  total  extracts  independent  of  the  ORF57 
presence (Fig. 6B, compare lanes 4-5 and 9-10 to lanes 
13-14), suggesting PABPC1 as an ORF57 partner pro-
tein specific in PAN MRE-II interaction.  
PAN RNA is exportable in the presence of 
ORF57 
 PAN  was  initially  discovered  as  a  nuclear 
non-coding RNA [28,32]. In chemical-induced BCBL1 
cells  with  ORF57  expression,  we  found  that  PAN 
RNA  was  partially  exported,  resulting  in  ~20%  of Int. J. Biol. Sci. 2011, 7 
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PAN RNA in the cytoplasm (Fig. 7A). This was spe-
cially true when PAN RNA was expressed in HeLa 
cells  and  HEK293  cells.  By  careful  fractionation  of 
HeLa cells and HEK293 cells with cotransfection of 
ORF57 and PAN as shown in Fig. 7B and 7C, a small 
fraction (~30%) of wt PAN were found in the cyto-
plasmic fraction of both HeLa (compare lane 2 to lane 
3 in Fig. 7B) and HEK293 (compare lane 1 to lane 2 in 
Fig. 7C) cells in the presence of ORF57. The similar 
results were also obtained from both cell lines by us-
ing a PANΔ3 mutant (see Fig. 2A) with deletion of the 
entire 3'-half region including the ENE (compare lane 
14 to lane 15 in Fig. 7B and lane 5 to lane 6 in Fig. 7C). 
Together, these data suggest a likelihood consequence 
of  nuclear  PAN  accumulation  in  the  presence  of 
ORF57.  
 
 
 
Fig. 6. MRE-II RNA interacts in vitro with ORF57 and other cellular proteins. (A) Mapping of an MRE binding site for ORF57. 
Shown on the top is a PAN MRE sequence lacking the MRE-I region in Fig. 4A, with the 9-nt core of MRE-II loop sequence 
bolded and underlined and the nt positions of biotinylated RNA oligomers employed in RNA pull-down assays. A cell lysate 
prepared from TREx BCBL-1-Rta cells [39] induced with Dox for 24 h was used for the RNA pulldown assays with an 
indicated RNA oligomer. The RNA oligo oNP42 derived from vIL-6 RNA [27] which binds ORF57 was used as a positive 
control. ORF57 associated with RNA oligos in the pulldowns was immunoblotted using an anti-ORF57 antibody. The cell 
lysate (10%) before the pulldown was loaded as a Western blot control. (B) Biotinylated RNA affinity pulldown analysis by 
Western blot using anti-ORF57, PABPC1 and E1B-AP5 antibodies. Total cell extract from TREx BCBL-1-Rta (R) or -vector 
(V) cells induced by Dox for 24 h was used for the RNA pulldown assays with each biotinylated RNA oligomer. RNA oligos 
oNP41 and oNP42 derived from vIL-6 RNA [27] were used, respectively, as a negative and positive oligomer control for 
ORF57 interaction and 10% of the cell lysate from each cell line before the pulldown was loaded for Western blotting 
control. RNA oligo oJM68 is a copy of oJM35 with the point mutations in the MRE-II loop described in Fig. 4B. Control beads 
indicate no RNA oligomer on the beads.  Int. J. Biol. Sci. 2011, 7 
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Fig. 7. A small proportion of PAN are exportable in ORF57-coexpressing cells. Total (T) and fractionated cytoplasmic (C) 
or nuclear (N) RNA from BCBL1 cells treated with or without valproate (VA, 1 mM) for viral lytic induction (A) or from 
HeLa cells (B) cotransfected with pJM1 (wt PAN), pJM2 (mt PANΔ1), or pJM4 (mt PANΔ3) in the presence (ORF57+) or 
absence (an empty vector control, ORF57-) of ORF57, were examined by Northern blot for PAN RNA expression. HEK293 
cells cotransfected with pJM1 (wt PAN), pJM2 (mt PANΔ1), or pJM4 (mt PANΔ3) in the presence of ORF57 were also 
fractionated and examined by Northern blot for PAN RNA expression (C). GAPDH RNA served as a control for sample 
loading and U6 RNA served as a fractionation efficiency control. The relative levels of PAN in each sample were calculated 
after normalization to GAPDH. 
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Discussion 
 We  previously  developed  a  high-throughput 
and genome-wide CLIP assay as a powerful tool to 
study ORF57 protein-RNA interactions in living cells 
[27].  This  CLIP  assay  allowed  us  to  identify  PAN 
RNA as the main target of ORF57. In this report we 
show  that  ORF57  binds  to  a  9-nt  core  sequence 
(UAUGGAUUU,  KSHV  nt  28704-28712)  in  the  loop 
structure of the PAN MRE-II to promote PAN accu-
mulation  by  increasing  its  half-life.  Moreover,  we 
found  that  the  PAN  MRE-II  also  interacts  with 
PABPC1 and E1B-AP5. More specifically, the 9-nt core 
sequence in the PAN MRE-II was identified for the 
binding of PABPC1, but not for E1B-AP5 [48], sug-
gesting that these two proteins by binding to different 
regions of the MRE-II may form a stable protein-RNA 
complex with ORF57 in accumulation of PAN RNA. 
Recently,  we  showed  that  ORF57  stabilizes  ORF59 
RNA by preventing aberrant ORF59 polyadenylation 
[26] and promotes the expression of vIL-6 and cellular 
IL-6 by preventing interactions of vIL-6 and cellular 
IL-6  RNAs  with  miR-1293  or  miR-608,  respectively 
[27]. In this report, we showed that another function 
of ORF57 is to prolong RNA half-life by binding to a 5' 
PAN MRE. Together with folding of all ORF57 CLIP 
sequences published in our previous report [27], these 
studies clearly indicate that ORF57 binding is RNA 
structure- and context-dependent and requires alter-
native  proteins  and  different  response  elements  to 
function. 
 Although  our  CLIP  assays  identified  three  re-
gions  of  PAN  RNA,  including  a  3'  region  encom-
passing the ENE previously reported in other studies 
[34-36],  in  association  with  ORF57  [27],  this  study 
demonstrated that only the 5' end of PAN operates as 
a functional MRE in ORF57-mediated PAN accumu-
lation. Deletion of other putative MREs from the in-
ternal region or the 3' region of PAN, including the 
ENE, had only a minimal effect on ORF57-mediated 
PAN  accumulation.  When  inserted  into  the  5'  UTR 
region of an ORF57 non-responding viral transcript 
vGPCR, however, the 84-nt MRE identified from the 
PAN 5' end was unable to efficiently promote accu-
mulation  of  the  tested  RNAs  in  the  presence  of 
ORF57.  This  indicates  that  other  regions  associated 
with  ORF57,  albeit  not  being  important  for  ORF57 
accumulation of PAN, might be needed to act as an 
auxiliary element to convert an ORF57 non-responder 
to an ORF57 responder. Moreover, further insertion of 
a 79-nt ENE to the 3' UTR of a luciferase transcript 
containing a PAN MRE in its 5' UTR did not provide 
additional effect to the PAN MRE on luciferase activ-
ity. Thus, the biological relevance of ORF57 binding to 
other PAN regions remains to be understood. 
 Consistent with our observations, a recent study 
also  reported  by  deletion  mutation  analysis  that 
ORF57 binds to a ~300-nt region (ORE) located on the 
5'  end  of  PAN  RNA  that  was  responsible  for  PAN 
accumulation [38]. By using a PAN-Δ79 (ΔENE) mu-
tant, ORF57 was proven to protect the mutant from 
RNA  decay.  Whether  ORF57  also  affects  wt  PAN 
half-life was not included in the report [38]. As we 
stated in Fig. 2 that ORF57 also binds to the ENE re-
gion in our CLIP assays and deletion of this region 
decreased ORF57 effect on PAN accumulation only by 
2-fold.  In  our  study,  both  wt  PAN  and  mt  PANΔ1 
lacking  the  MRE  were  examined  and  ORF57  was 
found to greatly prolong the wt PAN half-life from 
3.87 h to 12.2 h, but was impotent for the mt PANΔ1 
lacking  the  MRE-II  (Fig.  3).  Our  results  also  differ 
from Sahin’s report [38] on the roles of the identified 
MRE  in  heterologous  reporters.  We  were  unable  to 
find the functional 89-nt MRE being greatly active in 
the 5' UTR region of vGPCR or luciferase RNA in re-
sponse to ORF57. Although the ~300-nt ORE inserted 
to the β-globin 3' end was able to increase the β-globin 
response to ORF57 by 4-fold in Sahin’s study [38], we 
noticed that an approximate 3-fold increase of a re-
porter gene expression  in  the presence  of ORF57 is 
common  almost  for  any  testing  system.  An  RNA 
transcript with this level increase in the presence of 
ORF57  was  viewed  as  an  ORF57  non-responsive 
transcript,  such  as  vGPCR,  K5  and  luciferase  when 
compared  with  PAN  which  showed  a  ~30-fold  in-
crease in the presence of ORF57 in this report. Alter-
natively, the difference may be due to a larger piece of 
the ORE insertion at the 3' end of β-globin in Sahin’s 
study that put the testing ORE different from its na-
tive location in the PAN. 
 PABPC1  is  a  cytoplasmic  protein  involved  in 
mRNA  translation  initiation  and  stability  [49-52]. 
When  shuttled  to  the  nucleus,  PABPC1  engages  in 
nuclear RNA biogenesis [50,53,54]. In this study, we 
found that PABPC1 also binds to the 9-nt core of PAN 
MRE-II. E1B-AP5 or HNRNPUL1 (heterogeneous nu-
clear ribonucleoprotein U-like 1) has been implicated 
in the export of cellular mRNAs [48] by interacting 
with export protein TAP [55]. In addition, E1B-AP5 
activates  transcription  [56],  binds  p53  [57] and  par-
ticipates in DNA damage signaling pathways [58]. We 
found that E1B-AP5 interacts with the PAN MRE-II 
motif outside of the 9-nt core in the MRE-II loop, in-
dicating that E1B-AP5 binds to a different region in 
the  MRE-II  from  PABPC1.  Whether  the  binding  of 
these  two  proteins  to  the  PAN  MRE-II  is  also  im-
portant for ORF57 accumulation of PAN is under ac-Int. J. Biol. Sci. 2011, 7 
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tive  investigation.  Nevertheless,  our  data  clearly 
suggest  that  PABPC1  and  E1B-AP5  may  modulate 
PAN expression in complex with ORF57.  
Supplementary Material 
Fig.S1: Alignments of the CLIP sequences to PAN in 
ORF57 CLIP assays. Table S1: The list of all plasmids 
constructed or used in this study.  Table S2: The list of 
oligos used in this study.   
http://www.biolsci.org/v07p1145s1.pdf 
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